Navigation Links
YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
Date:9/4/2007

Data Presented at the 12th World Conference on Lung Cancer in Seoul, Korea

MISSISSAUGA, ON, Sept. 4 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced positive preliminary results from the first two cohorts of the Phase I part of a Phase I/II trial of nimotuzumab in combination with radiation for the treatment of non-small-cell lung cancer (NSCLC) patients who are unsuitable for radical chemotherapy. The data were reported on September 5th in a poster presentation at the 12th World Conference on Lung Cancer in Seoul, Korea. Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR).

"While preliminary, these results are compelling because we observed clinical benefit (Partial Response or Stable Disease) in every one of the 13 patients so far enrolled in this study. A study by The National Cancer Institute of Canada demonstrated that patients with advanced NSCLC with Stable Disease as best response for treatment had Overall Survival similar to patients with Partial Response. The relatively long survival times observed in the first cohort of this trial are encouraging and are in agreement with the NCIC observations," said Dr. Igor Sherman, YM's Director of Clinical Research. "Although nimotuzumab specifically targets the EGF receptor, the reported absence of side effects, particularly the absence of severe rash, makes nimotuzumab therapeutically attractive in this setting."

The Phase I component enrolled patients at three centers in Canada and is evaluating the safety and feasibility of administrating nimotu
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... VANCOUVER, British Columbia and ...   DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ... on developing and commercializing proven cancer therapies in ... data at the 106th Annual Meeting of ... Annual Meeting on the potential for its lead ...
(Date:4/20/2015)... April 20, 2015  Ardelyx, Inc. (NASDAQ: ... cardio-renal, gastrointestinal and metabolic diseases, today announced that ... the Company,s Board of Directors. Dr. Jenkins brings ... experience, having built and led teams advancing programs ... and into healthcare systems globally. ...
(Date:4/20/2015)... April 20, 2015  "Everybody is affected by cancer ... patients is frankly brutal. We,ve got to get away ... ward, or witnessed a loved one or friend battling ... the devastation chemotherapy and other treatments cause the human ... to give up and succumb to the disease. Dr. ...
(Date:4/20/2015)... Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical ... for the fourth quarter and full year ended December ... to the fourth quarter 2013) , Quarterly sales ... $22.9 million in the prior year period. Excluding revenue ... of $0.1 million in the fourth quarter of 2014 ...
Breaking Biology Technology:DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 2Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 4Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18
... The current revision of two European Directives that are ... the safety of patients and enhance their access to ... of a two-day conference, "Haematology and the next European ... doctors, researchers, parliamentarians, patients, organisations and Commission officials. ...
... Veracyte, Inc., a molecular diagnostics company pioneering the emerging ... from researchers at Johns Hopkins University School of Medicine ... Classifier for clarifying inconclusive results on thyroid nodule fine ... save the healthcare system money. According to the economic ...
... 2011 The medical imaging company SyntheticMR ... an order for their magnetic resonance imaging software from ... will be used in clinical practice to monitor the ... software, SyMRI Diagnostics, includes tools to automatically estimate a ...
Cached Biology Technology:Crucial Directives Must be Revised to Protect Patients' Interests and Improve Access to Treatment 2New Data Suggest Veracyte's Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results 2New Data Suggest Veracyte's Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results 3Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 2Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 3
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... researchers are working toward a future in which each ... how oncologists should treat the cancer to obtain the ... patients with prostate cancer should receive extra therapy after ... an indolent disease that does not even require surgery. ...
... working toward a future in which each patient's tumor ... should treat the cancer to obtain the best outcome. ... prostate cancer should receive extra therapy after surgery - ... disease that does not even require surgery. Most patients ...
... have designed a chip ?the GeneChip® Citrus Genome Array ... better manage them. By helping determine which genes are ... are associated with taste, acidic content and disease, for ... rectifying existing problems and making improvements to the fruit. ...
Cached Biology News:AIDS-related cognitive impairment exists in two separate forms 2AIDS-related cognitive impairment exists in two separate forms 3AIDS-related cognitive impairment exists in two separate forms 4AIDS-related cognitive impairment exists in two separate forms 5AIDS-related cognitive impairment exists in two separate forms 6AIDS-related cognitive impairment exists in two separate forms 7Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers 2Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers 3Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers 4Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers 5Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers 6Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers 7UCR researchers design chip that can improve citrus varieties 2UCR researchers design chip that can improve citrus varieties 3
... The Fujifilm Life Science FLA-7000 excels at ... CBB-stained gel documentation. It features four easy-to-access ... and a filter for Imaging Plates) for ... a customizable choice of four kinds of ...
... Software has been optimized for the analysis ... the software to quickly and accurately locate ... of an ELISA plate or each section ... has been customized to incorporate standard ELISA ...
For microscopy...
... in the base hold 10 l of ... hydration around the edges of the coverslip. ... waterbath contamination. This chamber can be used ... ovens. Linkage: This CLS number is a ...
Biology Products: